Slide 1: Q3'12 Results Conference Call
Q3’12 RESULTS Conference Call The Diagnostic Specialist
Slide 2: Highlights
Highlights 1
Slide 3: Main Topics
MAIN TOPICS Revenues: Strong seasonality effect as already experienced in Q3’11 CLIA sales ex Vitamin D growing double-digit and Vitamin D sales still affected by price effect in North America and Australia Strong performance in Emerging Markets (LatAm and Asia Pacific) Murex sales trend improving s
Slide 4: Q3'12 + 9M'12 Highlights and Trends
Q3’12 + 9M’12 HIGHLIGHTS AND TRENDS Q3’12 sales reflecting seasonality in the business as experienced in Q3’11, while continuously showing CLIA ex Vitamin D sales increasing double-digit and Murex business significantly growing - 0.7% Q3’12 vs. Q3’11 - 5.1% at cer Revenues - 2.2% 9M’12 vs. 9M’11 - 5
Slide 5: Revenues Breakdown: By Technology
REVENUES BREAKDOWN: BY TECHNOLOGY Double-digit growth in CLIA sales ex Vitamin D in Q3’12 and 9M’12, and Vitamin D sales stabilizing + 11.4% Q3’12 vs. Q3’11 CLIA sales ex Vitamin D + 11.9% 9M’12 vs. 9M’11 Vitamin d - 13.2% Q3’12 vs. Q3’11 - 13.9% 9M’12 vs. 9M’11 Murex business strongly supporting EL
Slide 6: Installed Base Enlargement
INSTALLED BASE ENLARGEMENT LIAISON + LIAISON XL installed base at September 30th, 2012 4.605 * units at September 30th, 2012 (from 4,206 at December 31st, 2011) New LIAISON XL systems installed in Q3’12 126 * new LIAISON XL installed in Q3'12 (480* at September 30th, 2012) 5 * Out of which 66 units
Slide 7: Revenues Breakdown: By Geography
REVENUES BREAKDOWN: BY GEOGRAPHy Amounts in millions of euros Q3 9m Q3’12/Q3’11 9M’12/9M’11 2012 2011 2012 2011 % % at CER % % at CER Europe and Africa 44.8 44.6 143.3 142.6 +0.5% -0.2% +0.5% +0.1% Central and South America 7.3 6.8 21.7 24.3 +6.6% +11.4% -10.8% -7.2% Asia Pacific 10.7 11.0 33.9 32.1
Slide 8: Business development
Business development 7
Slide 9: Business Development: Immunodiagnostics
BUSINESS DEVELOPMENT New products launches timeline respected: Immunodiagnostics Liaison HTLV-I Hepatitis and Retrovirus panel enrichment Liaison HTLV-II Further strengthening of ToRCH panel Liaison Rubella IgM Iam BKV Molecular Diagnostics ID panel enrichment Iam VZV Launch of LIAISON® Iam analyser
Slide 10: FY 2012 Pipeline
FY 2012 PIPELINE 2012 Q1 Q2 Q3 Q4 Hormonology Aldosterone IMMUNODIAGNOSTICS GI Stool Testing H. Pylori ✔ GDH Measles IgM ✔ Infectious Diseases Mumps IgM ✔ HTLV I/II ✔ VZV ✔ BKV ✔ MOLECULAR DIAGNOSTICS EBV Infectious Diseases PARVO TOXO CMV HSV 1-2 CML (BCR-ABL p210) CML (BCR-ABL p190) Onco Hematolog
Slide 11: Q3'12 and 9M'12 Financials
Q3’12 and 9M’12 FINANCIALS 10
Slide 12: Q3'12 & 9M'12 Results: Income Statement
Q3’12 & 9M’12 RESULTS: INCOME STATEMENT* €/mln 2012 2011 Change Q3 9M Q3 9M Q3/Q3 9M/9M Net Revenues 103.8 324.0 105.2 332.3 -1.3% -2.5% Gross profit 72.5 225.5 74.7 239.0 -3.0% -5.7% Gross margin 69.9% 69.6% 71.1% 71.9% S&M (20.0) (60.5) (18.7) (58.1) +6.7% +4.2% R&D (5.3) (16.9) (5.0) (15.7) +5.6%
Slide 13: Q3'12 & 9M'12 Results: Income Statement
Q3’12 & 9M’12 RESULTS: INCOME STATEMENT* 2012 2011 Change €/mln Q3 9M Q3 9M Q3/Q3 9M/9M Net Revenues 104.5 325.1 105.2 332.3 -0.7% -2.2% Gross profit 72.6 225.9 74.7 239.0 -2.9% -5.5% Gross margin 69.5% 69.5% 71.1% 71.9% S&M (20.2) (60.8) (18.7) (58.1) +7.8% +4.7% R&D (5.6) (17.3) (5.0) (15.7) +11.1
Slide 14: Balance Sheet at September 30th, 2012
BALANCE SHEET AT september 30 th, 2012 €/mln 09/30/2012 06/30/2012 03/31/2012 12/31/2011 Total intangible assets 126.2 126.4 121.7 121.9 Total tangible assets 64.2 64.0 61.3 62.7 Other non-current assets 20.5 21.0 20.3 20.7 Net Working Capital 137.1 140.3 139.5 133.9 Other non-current liabilities (2
Slide 15: Q3'12 & 9M'12 Results: Cash Flow Statement
Q3’12 & 9M’12 RESULTS: CASH FLOW STATEMENT 2012 2011 Change in value €/mln Q3 9M Q3 9M Q3/Q3 9M/9M Cash and cash equivalents at beginning of period 69.8 64.1 45.5 62.4 +24.3 +1.7 Operating activities 30.1 85.0 29.6 79.1 +0.5 +5.9 Financing activities 0.0 (28.3) 1.1 (53.5) -1.1 +25.2 Investing activi
Slide 16: FY 2012 Guidance
FY 2012 GUIDance Revenues in line with 2011 EBITDA margin in line with 2011 or slightly below 2011 level (~ 200 bps) 500-600 new systems installed (Liaison + Liaison XL) 15
Slide 17: Special Dividend
SPECIAL DIVIDEND Special dividend: Shareholders’ Meeting convened for: Dec 19, 2012 (first calling) Dec 20, 2012 (second calling) to vote on a motion to distribute a special dividend, drawn from Retained earnings Amount: 0.83 euros per share Total amount: 45,080,003.31 euros, not counting the 1,550,